249 related articles for article (PubMed ID: 24707134)
1. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease.
Sansone S; Guarino M; Castiglione F; Rispo A; Auriemma F; Loperto I; Rea M; Caporaso N; Morisco F
World J Gastroenterol; 2014 Apr; 20(13):3516-24. PubMed ID: 24707134
[TBL] [Abstract][Full Text] [Related]
2. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.
Sasadeusz J; Grigg A; Hughes PD; Lee Lim S; Lucas M; McColl G; McLachlan SA; Peters MG; Shackel N; Slavin M; Sundararajan V; Thompson A; Doyle J; Rickard J; De Cruz P; Gish RG; Visvanathan K
Clin Liver Dis; 2019 Aug; 23(3):521-534. PubMed ID: 31266625
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.
López-Serrano P; Pérez-Calle JL; Sánchez-Tembleque MD
World J Gastroenterol; 2013 Mar; 19(9):1342-8. PubMed ID: 23538480
[TBL] [Abstract][Full Text] [Related]
4. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection.
Morisco F; Castiglione F; Rispo A; Stroffolini T; Sansone S; Vitale R; Guarino M; Biancone L; Caruso A; D'Inca R; Marmo R; Orlando A; Riegler G; Donnarumma L; Camera S; Zorzi F; Renna S; Bove V; Tontini G; Vecchi M; Caporaso N
J Viral Hepat; 2013 Mar; 20(3):200-8. PubMed ID: 23383659
[TBL] [Abstract][Full Text] [Related]
5. [Prophylaxis of reactivation of hepatitis B and hepatitis C virus infection in immunosuppressive therapy].
Risum M; Barfod TS
Ugeskr Laeger; 2019 Feb; 181(6):. PubMed ID: 30729919
[TBL] [Abstract][Full Text] [Related]
6. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.
Degasperi E; Caprioli F; El Sherif O; Back D; Colombo M; Aghemo A
Expert Rev Gastroenterol Hepatol; 2016 Dec; 10(12):1373-1383. PubMed ID: 27718758
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus reactivation in inflammatory bowel diseases.
Kanmura S; Moriuchi A; Hamamoto H; Ido A
Nihon Rinsho; 2017 Mar; 75(3):461-465. PubMed ID: 30566792
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease.
Morisco F; Castiglione F; Rispo A; Stroffolini T; Vitale R; Sansone S; Granata R; Orlando A; Marmo R; Riegler G; Vecchi M; Biancone L; Caporaso N
Dig Liver Dis; 2011 Jan; 43 Suppl 1():S40-8. PubMed ID: 21195371
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B and C viral infections screening in a Tunisian IBD population under immunosuppressive therapies.
Sabbah M; Yacoub H; Bellil N; Trad D; Ouakaa A; Elloumi H; Bbani N; Gargouri D
Rev Gastroenterol Peru; 2020; 40(3):246-251. PubMed ID: 33181811
[TBL] [Abstract][Full Text] [Related]
10. Prevention of Hepatitis B reactivation in the setting of immunosuppression.
Pattullo V
Clin Mol Hepatol; 2016 Jun; 22(2):219-37. PubMed ID: 27291888
[TBL] [Abstract][Full Text] [Related]
11. Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease.
Coban S; Kekilli M; Köklü S
Inflamm Bowel Dis; 2014 Nov; 20(11):2142-50. PubMed ID: 25072501
[TBL] [Abstract][Full Text] [Related]
12. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.
Snast I; Atzmony L; Braun M; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Jul; 77(1):88-97.e5. PubMed ID: 28495497
[TBL] [Abstract][Full Text] [Related]
13. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management.
Zannella A; Marignani M; Begini P
Viruses; 2019 Sep; 11(9):. PubMed ID: 31540124
[TBL] [Abstract][Full Text] [Related]
14. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF
Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
16. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
Piaserico S; Messina F; Russo FP
Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
[TBL] [Abstract][Full Text] [Related]
17. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.
Loras C; Gisbert JP; Mínguez M; Merino O; Bujanda L; Saro C; Domenech E; Barrio J; Andreu M; Ordás I; Vida L; Bastida G; González-Huix F; Piqueras M; Ginard D; Calvet X; Gutiérrez A; Abad A; Torres M; Panés J; Chaparro M; Pascual I; Rodriguez-Carballeira M; Fernández-Bañares F; Viver JM; Esteve M; ;
Gut; 2010 Oct; 59(10):1340-6. PubMed ID: 20577000
[TBL] [Abstract][Full Text] [Related]
18. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
Ito S
Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
[TBL] [Abstract][Full Text] [Related]
19. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
